Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer
Abstract
The heterogeneity of androgen receptor (AR)-activity (AR-A) is well-characterized in heavily treated metastatic castration-resistant prostate cancer (mCRPC). However, the diversity and clinical implications of AR-A in treatment-naïve primary prostate cancer is largely unknown. We sought to characterize AR-A in localized prostate cancer and understand its molecular and clinical implications.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 15, 2019
- Source ID
- 10.1158/1078-0432.ccr-19-1587
Entities
People
- Adam B. Weiner
- Adam P. Dicker
- Arul Chinnaiyan
- Ashley E. Ross
- Brandon A Mahal
- Corey Speers
- Daniel E. Spratt
- Edward M. Schaeffer
- Elai Davicioni
- Felix Y. Feng
- Jonathan Lehrer
- Mohammed Alshalalfa
- Nick Fishbane
- Paul L. Nguyen
- R. Jeffery Karnes
- Robert B. Den
- Rohit Mehra
- Sheila Weinmann
- Shuang G. Zhao
- Stephen J. Freedland
- Tamara L Lotan
- Todd M Morgan
- Yang Liu
Organizations
- Cedars-Sinai Medical Center
- Harvard Medical School
- Johns Hopkins School of Medicine
- Mayo Clinic
- National Institutes of Health
- Northwestern University
- Prostate Cancer Foundation
- Thomas Jefferson University
- United States Department of Defense
- University of California
- University of Michigan